| Jennifer A Theis, PA | |
|
3333 Massillon Rd Ste 102, Akron, OH 44312-5982 | |
| (330) 896-3036 | |
| (330) 896-0464 |
| Full Name | Jennifer A Theis |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 21 Years |
| Location | 3333 Massillon Rd Ste 102, Akron, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972568046 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 50002095 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Akron General Medical Center | Akron, OH | Hospital |
| Cleveland Clinic | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Partners Physician Group | 4183529340 | 488 |
News Archive
BIOTRONIK SE Co. & KG highlights two key milestones toward receiving premarket approval (PMA) of the TactiCath, a novel technology for treating atrial fibrillation (AF): FDA IDE (investigational device exemption) approval and the first patient enrollment of the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical trial.
A recent study published in Pediatrics and led by researchers at Columbia University Mailman School of Public Health found that sugar-sweetened beverages (SSBs) are an increasingly large part of children and teens' diets.
For decades, researchers have suggested a link between oral health and inflammatory diseases affecting the entire body - in particular, heart attacks and strokes.
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer A Theis, PA 3226 Kent Rd, Stow, OH 44224-4429 Ph: (330) 929-3331 | Jennifer A Theis, PA 3333 Massillon Rd Ste 102, Akron, OH 44312-5982 Ph: (330) 896-3036 |
News Archive
BIOTRONIK SE Co. & KG highlights two key milestones toward receiving premarket approval (PMA) of the TactiCath, a novel technology for treating atrial fibrillation (AF): FDA IDE (investigational device exemption) approval and the first patient enrollment of the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical trial.
A recent study published in Pediatrics and led by researchers at Columbia University Mailman School of Public Health found that sugar-sweetened beverages (SSBs) are an increasingly large part of children and teens' diets.
For decades, researchers have suggested a link between oral health and inflammatory diseases affecting the entire body - in particular, heart attacks and strokes.
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
› Verified 9 days ago
Margaret S Sfiligoj, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-9634 Fax: 330-375-3769 | |
Brittany Johnson, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1622 E Turkeyfoot Lake Rd Ste 201, Akron, OH 44312 Phone: 330-776-4444 Fax: 330-776-4449 | |
Brittany Conner, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3975 Embassy Pkwy, Akron, OH 44333 Phone: 330-670-4242 | |
Mrs. Lara Renee Young, P.A.-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 150 Cross St, Akron, OH 44311 Phone: 330-996-9141 | |
Mr. Kodi Veale, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 3975 Embassy Pkwy, Akron, OH 44333 Phone: 330-668-4040 Fax: 330-668-4078 | |
Eric Bendel, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Christy A. Mackay, PAC Physician Assistant Medicare: Medicare Enrolled Practice Location: 1 Park West Blvd, Suite 200, Akron, OH 44320 Phone: 330-869-9777 Fax: 330-865-6011 |